| EPIC |
HLN |
| Sector |
Pharma and Biotech |
| ISIN |
GB00BMX86B70 |
| Market Sector |
MAIN |
| Market Segment |
SET1 |
| Main Indices |
FTSE 100, FTSE 350, FTSE All-Share |
| Country of register |
Great Britain |
| Currency |
British Pound |
| Market Cap |
£29,815m |
| NMS |
7,500 |
| Shares in issue |
8,847m |
| Date Listed |
n/a |
| |
Final |
Interim |
| Ex-Div |
09-Apr-26 |
14-Aug-25 |
| Paid |
14-May-26 |
18-Sep-25 |
| Amount |
4.90p |
2.20p |
| 16:49 |
3,322 @ 337.00p |
| 16:47 |
2,405 @ 334.75p |
| 16:47 |
167,912 @ 335.30p |
| 16:39 |
228,621 @ 337.00p |
| 16:37 |
9,288 @ 337.00p |
| CEO |
Brian McNamara |
| Chair |
Manvinder Singh (Vindi) Banga |
| CFO |
Dawn Allen |
Top of Page
You are here:
research